Search Results - "Reina Zoiló, J.J."

560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial by García Alfonso, P., Elez Fernandez, M.E., Soto Alsar, J., Paez, D., Fernandez Montes, A., Grana Suarez, B., Salud, A., Yubero Esteban, A., Gomez España, M.A., Macias Declara, I., Quintero Aldana, G.A., Lopez Lopez, C., Fernandez Rodriguez, T., Gravalos Castro, M.C., González-Flores, E., Guix Arnau, M., García Paredes, B., Reina Zoilo, J.J., Sastre Varela, J., Aranda Aguilar, E.

Get full text

Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study by Lopez Lopez, R., Reina Zoilo, J.J., Monge, D., Caballero, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Diaz Rubio, E., Garcia Foncillas, J., Feyjoo, M., Camps, C.

Get full text

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study by Sastre, J., García-Alfonso, P., Viéitez, J.M., Cano, M.T., Rivera, F., Reina-Zoilo, J.J., Salud-Salvia, A., Quintero, G., Robles-Díaz, L., Safont, M.J., La Casta, A., Gil, S., Polo, E., Asensio-Martínez, E., García-Paredes, B., López, R.L., Guillot, M., Valladares-Ayerbes, M., Aranda, E., Díaz-Rubio, E., Viéitez, J.M., Jiménez, P., Aguilar, E. Aranda, Gómez, A., Gil Calle, S., Salud, A., Valladares, M., Graña, B., García-Alfonso, P., Rivera, F., Quintero, G., Reina, J.J., González Flores, E., Salgado, M., Grande, E., Guillén, C., Garcia Carbonero, R., Flor, M.J., Safont, M.J., La Casta, A., Arévalo, S., Sastre, J., López López, R., Manzano, H., Guillot, M., Hernández Yagüe, X., Arrivi, A., Falcó, E., Gallego, J., Escudero, P., Cabezas, I., Juárez, A., Gálvez, E., Grávalos, C., Robles, L., Polo, E., Dueñas, R., Campos, J.M., Albert, A., Salinas, P., Montagut, C., Provencio, M., Ruiz Casado, A., Muñoz, J., Gil Raga, M., Chilet, M.R., González González, F.J., Massutí, B., López, A., Aparicio, J., Marín, M., Alfaro, J., Zanui, M., Gutiérrez Abad, D., García Tapiador, A.M., García-Girón, C., Molina Saera, J., Torres Sánchez, E., López, I., Bosch, C., Valero, J., Martínez de Prado, P.

“…We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan…”
Get full text

Efectividad y seguridad de imatinib en siete casos de tumores del estroma gastrointestinal by Giménez Castellanos, J., Sánchez Gómez, E., Reina Zoiló, J.J., Gabella Bazarot, E., Marín Ariza, I., Grutzmancher Saiz, S.

“…Medir la efectividad y seguridad de imatinib en los tumores del estroma gastrointestinal (GIST). Estudio retrospectivo desde el año 1993 hasta junio de 2005…”
Get full text